Morgan Stanley raised the firm’s price target on Alnylam (ALNY) to $287 from $268 and keeps an Equal Weight rating on the shares. Alnylam’s Q1 was in line with expectations, and Amvuttra in Transthyretin Amyloid Cardiomyopathy represents a key growth driver, the analyst tells investors in a research note. Early launch trends for Amvuttra are “favorable” and “encouraging,” with management highlighting broad use and access, which should bode well for a strong launch, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma: Strong Financial Performance and Promising Growth Catalysts Justify Buy Rating
- Alnylam Pharma: Strong Buy Rating Driven by Robust RNAi Portfolio and Market Expansion
- Alnylam Pharma: Hold Rating Amid EU Approval Prospects and Pricing Challenges
- ALNY Earnings this Week: How Will it Perform?
- Alnylam Pharma’s Promising Outlook in the ATTR-CM Market: A Buy Recommendation by Maury Raycroft